Browsing: lung cancer

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

The eight priority cancer types identified by the DoH include the following. They are breast cancer, childhood cancers, gynecologic cancers, liver cancer (including colorectal and other digestive tract cancers), head and neck cancers (including thyroid), lung cancer, and prostate, renal, and urinary bladder cancer. The CAF aims to address the most pressing needs within cancer care and treatment by focusing on these priority areas.

Each cancer type presents unique challenges in prevention, early detection, and treatment. The allocation of funds for these specific areas reflects a strategic approach to resource allocation. This ensures that interventions are targeted and effective in addressing the burden of cancer across different population groups.

World Cancer Day held every 4 February since 2000 is the global uniting initiative led by the Union for International Cancer Control (UICC).

Asia contributes to around 59.6% of all lung cancer cases, globally. Read more to learn how lung cancer occurs in non-smokers.

Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more

People with COPD are not able to fully exhale what they have inhaled. Learn more about COPD with Dr Elizabeth Yu, pulmonologist @UCSF.

Lung cancer accounts for 14.1% of newly diagnosed cancers and 20% of cancer deaths worldwide. 59% of the world’s lung…

Lung cancer is one of the most common causes of cancer-related disability and death in the world. It begins in…